U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. News & Events for Human Drugs
  4. Overview: Clinical Pharmacology Considerations for Neonatal Studies - 02/15/2023
  1. News & Events for Human Drugs

Virtual | Virtual

Event Title
Overview: Clinical Pharmacology Considerations for Neonatal Studies
February 15, 2023

Date:
February 15, 2023
Time:
1:00 PM - 2:00 PM ET

Topic & Presentations

Speakers

Overview: Clinical Pharmacology Considerations for Neonatal Studies

 

A Pediatric Research Imperative: Addressing Neonates in Drug Development

Dionna Green
Director
Office Pediatric Therapeutics (OPT)
Office of the Commissioner (OC) | FDA

Clinical Considerations for Neonatal Drug Development

An Massaro
Supervisory Medical Officer
OPT | OC | FDA

Clinical Pharmacology of Neonates and Considerations for Study Design

Elimika Pfuma Fletcher
Policy Lead and Senior Clinical Pharmacologist
Office of Clinical Pharmacology (OCP)
Office of Translational Sciences (OTS)
CDER | FDA

Q&A Discussion Panel

Dionna Green, An Massaro, and Elimika Pfuma Fletcher

Visit CDER Small Business and Industry Assistance Page

ABOUT THIS WEBINAR

In this webinar, FDA will discuss:

  • An overview of the current status and the gaps related to the inclusion of neonates in drug development
  • Clinical pharmacology considerations for planned studies in neonates
  • General pharmacokinetic, pharmacodynamic, and pharmacogenomic considerations for clinical pharmacology studies in neonates
  • Unique clinical and study design considerations for studying neonates
  • Innovative approaches that can be incorporated into study design to address unique challenges in neonates

TOPICS COVERED

  • Defining neonatal subpopulations that can be used for study design and study results reporting
  • Clinical pharmacology and study design considerations for neonatal studies
  • Innovative approaches to study design and analysis to address unique challenges in performing clinical trials in neonates

LEARNING OBJECTIVES

  • Describe how neonatal subpopulations can be defined for the purposes of study design and reporting
  • Discuss clinical pharmacology considerations for clinical studies in neonates for drug development
  • Discuss innovative approaches that can be incorporated into study design to address unique challenges in conducting neonatal studies

INTENDED AUDIENCE

  • Regulatory science and regulatory affairs professionals working on submission of investigational new drug applications (INDs) and applicants of new drug applications (NDAs), biologics license applications (BLAs), and supplements to such applications who are planning to conduct clinical studies in neonatal populations
  • Researchers working on clinical pharmacology and clinical studies in the pediatric population including neonates
  • Consultants focused on clinical pharmacology and clinical studies in the pediatric population including neonates
  • Clinical research coordinators involved in studies conducted in the pediatric population including neonates
  • Healthcare professionals specializing in pediatrics including neonates
  • Foreign regulators

FDA SPEAKERS

A Pediatric Research Imperative: Addressing Neonates in Drug Development
Dionna Green
Director
Office Pediatric Therapeutics (OPT) | Office of the Commissioner (OC) | FDA

Clinical Considerations for Neonatal Drug Development
An Massaro
Supervisory Medical Officer
OPT | OC | FDA

Clinical Pharmacology of Neonates and Considerations for Study Design
Elimika Pfuma Fletcher
Policy Lead and Senior Clinical Pharmacologist
Office of Clinical Pharmacology (OCP) | Office of Translational Sciences (OTS) | CDER | FDA

FDA RESOURCES

Event Materials

Title File Type/Size
Clinical Pharmacology Considerations for Neonatal Studies_February 15, 2023 pdf (1.93 MB)
Back to Top